Navigation Links
ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting
Date:10/24/2007

Enrollment completed in separate Phase II study in Carotid Atherosclerosis

LEXINGTON, Mass., Oct. 24 /PRNewswire/ -- ActivBiotics, Inc. today announced that the results of its pivotal clinical trial (PROVIDENCE-1) studying the effect of rifalazil in the treatment of intermittent claudication associated with peripheral arterial disease (PAD) will be presented on November 7, 2007 at 11:45 a.m. EST at a late breaker Scientific Session at the American Heart Association's 2007 annual meeting being held in Orlando, Florida. Michael R. Jaff, DO, FACP, FACC, Assistant Professor of Medicine, Harvard Medical School and Medical Director, Massachusetts General Hospital Vascular Center, Boston, Massachusetts, Chair of the trial's Steering Committee, will be presenting.

PROVIDENCE-1 (Prospective Evaluation of Rifalazil Effect on Vascular Symptoms of Intermittent Claudication and Other Endpoints in Chlamydia Seropositive Patients) is the first of two planned Phase III clinical trials to study the ability of rifalazil to improve symptoms in patients suffering from intermittent claudication, an often debilitating and under diagnosed manifestation of PAD. The prospective, double-blind, randomized, placebo- controlled trial evaluated the efficacy and safety of rifalazil in 297 patients from the United States, Russia and Brazil. The FDA has granted rifalazil Fast Track designation for development in this indication.

In addition to the PROVIDENCE-1 Phase III clinical trial, a Phase II study to evaluate the effect of rifalazil on the progression of carotid artery atherosclerosis has completed its target enrollment of 72 patients. The RESTORE-IT trial (Randomized Evaluation of Short-Term Rifalazil Treatment on Carotid Atherosclerosis and Intima Media Thickness) is a prospective, randomized, double-blind, placebo-controlled, multi-center study of patients with a clinical history of atherosclerosis and image-detectable carotid disease. This study will use the non-inva
'/>"/>

SOURCE ActivBiotics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Oct. 1, 2014 NeuroCall, Inc., ("NeuroCall") announced ... its Telestroke and Teleneurology services. Dr. Ricardo Garcia-Rivera ... "We are extremely proud that our quality of service ... continue to provide lifesaving support and continuity of care ... throughout the United States ." ...
(Date:10/1/2014)... , Oct. 1, 2014 Quantum Materials ... volume production of photoactive quantum dots for use ... While offering numerous advantages for solar power generation, ... quantities of quantum dots with which to develop ... them from commercial utilization and acceptance. The company ...
(Date:10/1/2014)... 1, 2014 Sophia Genetics, ... domaine de l,analyse des données issues du SNG ... de diagnostic in vitro (IVD) du gène CFTR ... la mucoviscidose dans un seul essai SGN. La ... les types de variantes par l,intermédiaire d,un seul ...
Breaking Medicine Technology:NeuroCall Awarded Joint Commission Accreditation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3
(Date:10/1/2014)... 2014) Despite a policy focus on expanding ... this vulnerable population continues to have significant dental ... Journal of the American Dental Association , researchers ... University School of Dental Medicine report on the ... oral care provided by caregivers to adults with ...
(Date:10/1/2014)... Familylifeinsurancequotes.org has released a new blog ... citizens. , Senior citizens can qualify for affordable ... to seniors who are over 50 years old. Some ... a medical examination. , Term life insurance with a ... can qualify. Having life insurance during retirement is important ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Insuranceragents.info ... find a good life insurance plan for vulnerable family ... for vulnerable family members. Providers in the family should ... will cause financial hardships for the rest of the ... of policies. Families can benefit more from temporary coverage ...
(Date:10/1/2014)... Lifeinsurance-policy.com has released a new blog ... prices for smokers. , Smoking will always have a ... is the best method to find affordable coverage. Insurance ... need coverage. , Whole life insurance premiums will ... Since the coverage is permanent, the initial rates ...
(Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... the business worldwide. This rapid growth includes increased hiring ... manufacturing efforts. The company has experienced average annual growth ... expects this growth to continue in the future as ... adoption. , “We are very pleased that ...
Breaking Medicine News(10 mins):Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:Phoseon Technology Continues to Drive Growth Worldwide 2
... too, DENVER, Jan. 30 With the high ... want to heed advice,from two of the country,s leading ... speeches and pep rallies leading up to February 5, ... trail such as cheering,supporters, political pundits, and media analysts, ...
... Regional Healthcare System has,selected TransUnion,s Healthcare Revenue Cycle ... streamline administration of its charity,care policy., The ... hospital,system with campuses in Elyria, Amherst, and Avon, ... has served the needs of Lorain County and,greater ...
... 30 Sports and,nutritional product manufacturer, Natural Nutrition ... today a forward split of,its common stock. Each ... for every four shares owned as of the ... of record as of February 8, 2008, will ...
... stimulation (DBS) surgery, which is used to treat Parkinsons ... for its potential to treat a variety of conditions. ... to treat cluster headaches and aggressiveness in humans, and ... new study found that hypothalamic DBS performed in the ...
... Control No Matter Where,You Live, WASHINGTON, Jan. 30 ... the #1 Asthma Capital(TM) -- the most,challenging place to live ... Foundation of America (AAFA)., Since 2004, AAFA has conducted ... in America and to rank,them based on the quality of ...
... Jan. 29 John Josef Molenda has joined ... in the Firm,s Intellectual Property,and Appellate and Supreme ... an associate at Frommer Lawrence & Haug,LLP, where ... patent litigation. Dr. Molenda, who has a Ph.D. ...
Cached Medicine News:Health News:Candidates Risk Harming Voice in Final Week to Super Tuesday 2Health News:EMH Regional Medical Center Selects TransUnion's Healthcare Revenue Cycle Platform to Help Reduce Its Bad Debt 2Health News:EMH Regional Medical Center Selects TransUnion's Healthcare Revenue Cycle Platform to Help Reduce Its Bad Debt 3Health News:Natural Nutrition Announces Forward Split of Common Stock 2Health News:Deep brain stimulation may improve memory 2Health News:Asthma Foundation Announces 2008 Asthma Capitals, Knoxville on Top Again 2Health News:Asthma Foundation Announces 2008 Asthma Capitals, Knoxville on Top Again 3
The clarity and performance of glass with shatterproof safety of plastic....
Accurate and easy hematocrits in two minutes. Choose glass or easy to read SafeCrit plastic tubes, plain or heparinized. These tubes feature rapid capillary action and have a two-year shelf life. For...
... In the Innova™ 4100, the ... X-ray system for angiographic imaging, ... piece, non tiled Digital Detector ... reliably provide high resolution imaging ...
... is a bench-top fully automated random ... host of features usually only seen ... has the capacity to perform up ... ISEs, and offers primary tube sampling, ...
Medicine Products: